Cefazolin-ACOS solution 1g vial, 50pcs

Composition

1 bottle contains cefazolin (in the form of sodium salt) 1,0 g

Pharmacological action

Cefazolin is a cephalosporin antibiotic of the first generation for parenteral use. It acts bactericidal, disrupting the synthesis of the cell wall of microorganisms. It has a wide spectrum of action, is active against: gram-positive bacteria (Staphylococcus spp, Staphylococcus aureus (non-producing and penicillinase producing; including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis); gram-negative microorganisms (Neisseria meningitidis, Neisseria gonorrhoeae, Shigella spp, Salmonella spp, Escherichia coli, Klebsiella spp, Treponema spp, Leptospira spp); active against Haemophilus influenzae; some strains of Enterobacter and Enterococcus. It is ineffective against: Pseudomonas aeruginosa, indole-positive strains of Proteus spp, Mycobacterium tuberculosis, anaerobic microorganisms, methicillin-resistant strains of Staphylococcus spp.

Indications

-Bacterial infections of the upper and lower respiratory tract, urinary and biliary tract, pelvic organs, skin and soft tissues, bones and joints. – Endocarditis. – Sepsis. – Peritonitis. – Otitis media. – Osteomyelitis. – Mastitis. – Wound, burn and postoperative infections. – Syphilis. – Gonorrhea. – Other diseases caused by microorganisms sensitive to cefazolin. – Prevention of surgical infections in the pre-and postoperative period.

Contraindications

: Hypersensitivity to cephalosporin drugs and other beta-lactam antibiotics. – Pregnancy and lactation. – If it is necessary to use the drug, stop breastfeeding. – Does not prescribe to newborns (up to 1 month). With caution:  – Renal / hepatic insufficiency. – Pseudomembranous enterocolitis.

Interaction

Concomitant use with anticoagulants and diuretics is not recommended. With the simultaneous use of cefazolin and “loop diuretics”, its tubular secretion is blocked. Aminoglycosides increase the risk of developing kidney damage Pharmacologically incompatible with aminoglycosides (mutual inactivation). Drugs that block tubular secretion increase blood concentrations, slow down excretion, and increase the risk of toxic reactions.

How to take, course of use and dosage

Intravenously, intramuscularly (jet and drip). The average daily dose for adults is 1 g, the frequency of use is 2 times a day. The maximum daily dose is 6 g (in rare cases-12 g); the frequency of use can be increased to 3-4 times a day. The average duration of treatment is 7-10 days. For the prevention of postoperative infection:  30 minutes before surgery,0.5-1 g. During the operation and 0.5-1 g every 6-8 hours during the day after the operation. Use in patients with impaired renal function:  if the creatinine clearance is 55 ml / min or more, or if the plasma creatine content is 1.5 mg% or less, the full dose can be administered. With a creatinine clearance of 54-35 ml / min or with a plasma creatinine content of 3-1.6 mg%, the full dose can be used, but the intervals between injections can be increased to 8 hours. Patients with creatinine clearance of 34-11 ml / min or a plasma creatinine content of 4.5-3.1 mg%-1 / 2 doses at intervals of 12 hours. Patients with creatinine clearance of 10 ml / min or less, or with a plasma creatinine content of 4.6 mg% or more-1/2 of the average dose every 18-24 hours. Use in children: the average daily dose for children is 20-50 ml / kg; in severe cases of infection, the dose can be increased to 100 mg/day. The frequency of maintenance is 3-4 times a day. Use in children with impaired renal function:  in children with impaired renal function, the dosage regimen is adjusted depending on the values of creatinine clearance. With a creatinine clearance of 70-40 ml / min – 60% of the average daily dose and removed after 12 hours. With a creatinine clearance of 40-20 ml / min – 25% of the average daily dose with an interval of 12 hours. Children with creatinine clearance of 5-20 ml / min – 10% of the average daily dose every 24 hours. All recommended doses are administered after the initial shock dose. Preparation of solutions:  for intramuscular use, the drug is dissolved in 4-5 ml of water for injection, an isotonic solution of sodium chloride or 0.25-0.5% novocaine solution. For intravenous drip use, the drug is dissolved in 100-250 ml of isotonic sodium chloride solution or 5% glucose solution; the injection is carried out for 20-30 minutes (the rate of use is 60-80 drops per minute). For intravenous jet use, a single dose of the drug is diluted in 10 ml of isotonic sodium chloride solution and administered slowly for 3-5 minutes. During dilution, the vials are shaken vigorously until completely dissolved.

Complete

set50 vials per pack. 

Special instructions

Patients who have had a history of allergic reactions to penicillins, carbapenems, may have an increased sensitivity to cephalosporin antibiotics. During treatment with cefazolin, it is possible to obtain positive direct and indirect Coombs tests, as well as a false positive reaction of urine to sugar. When prescribing the drug, an exacerbation of gastrointestinal diseases, especially colitis, is possible. The safety of use in premature children and children of the first year of life has not been established.

Form of production

Powder for preparing a solution for intravenous and intramuscular use.

Active ingredient

Cefazolin

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Indications

Tonsillitis, Pharyngitis, Urinary Tract Infections, Vaginal Infections, Bronchitis, Sinusitis, Otitis Media, Skin Infections